Whether the delivery of IL-2 and TGF-β, which are deficient in SLE, mediated by nanoparticles (NPs) to mouse CD2+ and CD4+ cells, could induce a tolerogenic immune response and then protect mice from a lupus-like disorder was investigated (64, 65). Here, TGFB1 is linked to systemic lupus erythematosus.